The clinical observation of urinary kallidinogenase in treatment of acute cerebral infarct patients with diabetes mellitus
LIU Shi-ying,ZHANG Kun-nan,CAO Wen-feng,QU Xin-hui,XIE Xu-fang,WU Xiao-mu
2010-01-01
Abstract:Objective To observe the therapeutic effects of urinary kallidinogenase and edaravone on acute cerebral infarct patients with type 2 diabetes mellitus. Methods In this study, 63 acute cerebral infarct patients with type 2 diabetes mellitus were divided into two groups randomly: urinary kallidinogenase and edaravone therapy group (therapy group, n=29, urinary kallidinogenase 0.15PNA unit, intravenous drip, once per day, for 14 days. Edaranove 30mg, intravenous drip, twice per day, for 14 days) and edaravone therapy group (control group, n=34). Both groups were given the same antiplatelet, cholesterol lowing, cerebral nerve nutriceutical, etc. routine treatment. Meanwhile, both groups were given the glucose control. The degree of neurologic impairment of the two groups was observed and evaluated by NIHSS, MRS, and ADL before treatment and two weeks and four weeks of the treatment. Results Comparing with control group, NIHSS score, MRS score, and ADL score of therapy group were higher significantly(P<0.05). The sexuality constituent ratios, age, plasma glucose control of both groups were not difference. Furthermore, nonsignificant was the difference in the blood pressure, NIHSS, MRS and ADL before treatment in therapy group and control group. During study, in comparison with control group, blood pressure of therapy group was lower. However, on the end of a week, comparing with control group, mean arterial pressure of therapy group was decreased significantly (P<0.05). In the period of study, there was no hypotension or cerebral hypoperfusion incident. Conclusion Effects of Urinary kallidinogenase and edaravone on acute cerebral infarct patients with type 2 diabetes mellitus were more benefit than that of edaravone.